Fig. 6
Lipidomic analysis of the PFC of mice treated with cisplatin and bexarotene. Quantification of the peak intensity of different lipid subclasses in prefrontal cortex of mice treated with cisplatin and bexarotene. Results are expressed as mean ± SD. n = 4 mice/group. *p < 0.05, **p < 0.01. Cer ceramides, CerG1 monoglycosylceramide, DG diacyl-glycerols, dMePE dimethylphosphatidylethanolamine, LdMePE lysodimethylphosphatidyl-ethanolamine, LPC lysophosphatidylcholine, LPE lysophosphatidylethanolamine, LPG lysylphosphatidylglycerol, LPI lysophosphatidylinositol, LPS lipopoly-saccharide, MG monoradylglycerolipids, MGDG monogalactosyl diacylglycerol, OAHFA (O-acyl)-ω-hydroxy FA, PA phosphatidic acid, PC phosphatidylcholines, PE phosphatidyl-ethanolamines, PG phosphatidylgylcerols, PL phospholipids, PMe phosphatidyl-(N)-methylethanolamine, PS phosphatidylserine, SM sphingomyelin, TG triglyceride, ZyE zymosterol